Mobile

A randomized, 24-week, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE agai...

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-005404-13

A randomized, 24-week, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE against thyreoperoxidase

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that omalizumab, compared to omalizumab-Placebo, has superior efficacy as for urticaria activity score (UAS7) after 24 weeks of treatment in adult patients with moderate to severe chronic urticaria who exhibit IgE against thyreoperoxidase.

Critère d'inclusion

  • Chronic urticaria

Liens